Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 3/20 | 0.56 |
| ▸ | GABRB2 | P47870 | 2/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.52 |
| ▸ | CA2 | P00918 | 3/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.52 |
| ▸ | HPGD | P15428 | 2/20 | 0.52 |
| ▸ | GABRG2 | P18507 | 2/20 | 0.52 |
| ▸ | GABRB3 | P28472 | 2/20 | 0.52 |
| ▸ | FAAH | O00519 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 1/20 | 0.52 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.52 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5548772 | 0.84 | GABRA1 (0.50) | GABRA1GABRB2CA1CA2TSHR | |
| SCHEMBL16950843 | 0.84 | CA1 (0.46) | GABRA1GABRB2CA1CA2TSHR | |
| SCHEMBL11039264 | 0.83 | CA1 (0.48) | GABRA1GABRB2CA1CA2TSHR | |
| SCHEMBL11040447 | 0.83 | GABRA1 (0.56) | GABRA1GABRB2CA1CA2TSHR | |
| SCHEMBL28998308 | 0.82 | CA1 (0.47) | GABRA1GABRB2CA1CA2TSHR | |
| 2-Methoxyresorcinol SCHEMBL69297 | 0.79 | CA2 (0.61) | CA1CA2TSHRLMNACYP3A4 | |
| SCHEMBL7149154 | 0.77 | ADRA2A (0.47) | CA1CA2LMNACYP3A4HPGD | |
| SCHEMBL6062443 | 0.77 | GABRA1 (0.53) | GABRA1GABRB2CA1CA2TSHR | |
| SCHEMBL28789370 | 0.77 | PABPC1 (0.46) | GABRA1GABRB2CA1CA2TSHR | |
| SCHEMBL16961291 | 0.77 | CA1 (0.47) | GABRA1GABRB2CA1CA2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | MEDICONNS SHANGHAI BIOPHARMACEUTICAL CO LTD (CN) | 2021-01-28 | — | — | US | disclosed |
| US-9579325-B2 | Modulators of TNF-α signaling | GENZYME CORPORATION (US) | 2017-02-28 | — | — | US | disclosed |
| CN-103370318-B | The Imidazopyridazine replaced | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-04-20 | — | — | CN | disclosed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| US-9255100-B2 | Substituted imidazopyridazines | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-02-09 | — | — | US | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| EP-2614063-B1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER IP GMBH (DE) | 2016-01-13 | — | — | EP | disclosed |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-12-19 | — | — | US | disclosed |
| CN-103370318-A | Substituted imidazopyridazines | BAYER IP GMBH | 2013-10-23 | — | — | CN | disclosed |
| EP-2614063-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | Bayer Intellectual Property GmbH (DE) | 2013-07-17 | — | — | EP | disclosed |
| WO-1984000566-A1 | IMPROVED CELL FOR ELECTROLYTIC PRODUCTION OF ALUMINUM | MARTIN MARIETTA CORP (US) | 1984-02-16 | — | — | WO | disclosed |
| WO-1984000565-A1 | ALUMINUM CATHODE COATING CURE CYCLE | MARTIN MARIETTA CORP (US) | 1984-02-16 | — | — | WO | disclosed |
| EP-0096282-A2 | Light-sensitive compounds for positive photoresist materials | MERCK PATENT GmbH (DE) | 1983-12-21 | — | — | EP | disclosed |
| EP-0043953-B1 | ALUMINIUM TRIHYDRATE MODIFIED ZINC-RICH COATINGS | UNION CARBIDE CORPORATION (US) | 1983-11-09 | — | — | EP | disclosed |
| US-4370382-A | CONTAINING EPOXY RESIN, ZINC PIGMENTS AND ZINC PHOSPHOSILICATE CORROSION RESISTANCE | UNION CARBIDE CORPORATION (US) | 1983-01-25 | — | — | US | disclosed |
| EP-0070008-A2 | Aluminum thrihydrate modified zinc-rich coatings | UNION CARBIDE CORPORATION (US) | 1983-01-19 | — | — | EP | disclosed |
| EP-0043953-A2 | Aluminium trihydrate modified zinc-rich coatings | UNION CARBIDE CORPORATION (US) | 1982-01-20 | — | — | EP | disclosed |
| US-4294911-A | AND A QUATERNARY ALKANOL AMMONIUM HYDROXIDE DEVELOPING AGENT | EASTMAN KODAK COMPANY (US) | 1981-10-13 | — | — | US | disclosed |
| US-4141733-A | Development of light-sensitive quinone diazide compositions | EASTMAN KODAK COMPANY (US) | 1979-02-27 | — | — | US | disclosed |
| US-4115128-A | Positive image forming radiation sensitive compositions containing diazide compound and organic cyclic anhydride | FUJI PHOTO FILM CO., LTD. (JP) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210024498-A1 | TETRAHYDROPYRROLE COMPOUND, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND USE THEREOF | PRLHR, DRD2, AVPR2 | GABRA1 91/4885GABRB2 254/4885CA1 4660/4885 |
| US-20130338133-A1 | SUBSTITUTED IMIDAZOPYRIDAZINES | BUB1, TTBK1, BUB1B | GABRA1 2772/4885GABRB2 3757/4885CA1 4722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.